

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	4Q `08	4Q `07	YTD 2008	YTD 2007
MERCK / SCHERING-PLOUGH	\$ 378.1	\$ 537.7	\$ 1,536.3	\$ 1,830.8
ASTRAZENECA LP	266.8	211.8	598.4	820.1
Other ⁽¹⁾	75.1	46.8	425.9	325.6
TOTAL	\$ 720.0	\$ 796.3	\$ 2,560.6	\$ 2,976.5

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	4Q `08	4Q `07	YTD 2008	YTD 2007
FRONTLINE, other fipronil	\$ 152.0	\$ 167.2	\$ 1,053.0	\$ 1,033.3
BIOLOGICALS	208.8	202.1	789.7	674.9
IVOMEK, HEARTGARD, other avermectins	96.8	111.7	511.8	478.4
Other Animal Health	67.4	70.2	288.2	262.2
TOTAL MERIAL SALES	\$ 525.0	\$ 551.2	\$ 2,642.7	\$ 2,448.8

Sanofi Pasteur-MSD	4Q `08	4Q `07	YTD 2008	YTD 2007
GARDASIL	\$ 171.2	\$ 231.0	\$ 865.3	\$ 476.0
VIRAL VACCINES	24.4	21.8	105.1	86.8
HEPATITIS VACCINES	15.9	19.0	72.6	72.9
Other Vaccines	265.1	267.3	841.8	802.3
TOTAL SANOFI PASTEUR-MSD SALES	\$ 476.6	\$ 539.1	\$ 1,884.8	\$ 1,438.0

Merck / Schering-Plough Collaboration	4Q `08	4Q `07	YTD 2008	YTD 2007
VYTORIN	\$ 549.5	\$ 775.9	\$ 2,360.0	\$ 2,779.1
ZETIA	524.7	678.6	2,201.1	2,407.1
TOTAL MERCK / SCHERING-PLOUGH SALES	\$ 1,074.2	\$ 1,454.5	\$ 4,561.1	\$ 5,186.2

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	4Q `08	4Q `07	YTD 2008	YTD 2007
INTEREST INCOME	\$ (147.2)	\$ (200.2)	\$ (631.4)	\$ (741.1)
INTEREST EXPENSE	56.7	87.1	251.3	384.3
EXCHANGE LOSSES (GAINS)	73.8	(14.5)	147.4	(54.3)
MINORITY INTERESTS	30.0	29.4	123.9	121.4
Other, net ⁽¹⁾	(10.1)	665.6	(2,085.4)	335.9
TOTAL	\$ 3.2	\$ 567.4	\$ (2,194.2)	\$ 46.2

⁽¹⁾ Other, net for full year 2008 primarily reflects a gain of \$2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of \$671.1 million.

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2008

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	4Q '08 vs. 4Q '07					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	-1%	881	-3%	319	-	562
FOSAMAX	-60%	318	-85%	77	-12%	241
SINGULAIR	-3%	1,122	-11%	709	15%	413
Vaccines:						
GARDASIL	-16%	286	-19%	216	-2%	69
ROTATEQ	9%	162	4	148	*	14
ZOSTAVAX	89%	162	89%	162	N/A	-
OTHER VIRAL VACCINES ⁽¹⁾	-10%	295	-11%	278	3%	17
HEPATITIS VACCINES ⁽²⁾	-33%	40	-32%	33	-38%	7
OTHER VACCINES ⁽³⁾	5%	132	8%	97	-2%	35
Other Reported Products:						
ARCOXIA	-1%	83	N/A	-	-1%	83
CANCIDAS	4%	139	4%	21	4%	118
COSOPT / TRUSOPT	-27%	154	-62%	37	1%	117
CRIVAN / STOCRIN	-35%	52	-34%	3	-35%	49
EMEND	16%	71	23%	47	6%	24
INVANZ	29%	68	35%	38	21%	30
ISENTRESS	*	130	*	71	*	59
JANUVIA	64%	413	41%	323	*	89
JANUMET	*	120	*	99	*	20
MAXALT	12%	141	15%	97	7%	44
PRIMAXIN	-13%	169	-24%	39	-10%	130
PROPECIA	-4%	108	-5%	37	-3%	71
PROSCAR	-14%	72	-46%	2	-12%	69
TIMOPTIC / TIMOPTIC XE	-3%	31	-9%	2	-3%	29
VASOTEC / VASERETIC	-32%	85	N/A	-	-32%	85
ZOCOR	-34%	147	-80%	11	-19%	136
ZOLINZA	64%	5	62%	4	*	-

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

TOTAL PHARMACEUTICAL SALES	4Q '08 \$	% CHG	VOL	PX	FX
	6,032	-3%	-4	1	-1
U.S. (\$ MM)	3,396	-9%	-12	4	N/A
Foreign (\$ MM)	2,636	5%	10	-3	-2

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
DECEMBER YEAR-TO-DATE
2008

NET PRODUCT SALES DETAIL (millions of dollars)

PRODUCT	DECEMBER YTD `08 vs. DECEMBER YTD `07					
	TOTAL % CHG	TOTAL \$	U.S. % CHG	U.S. \$	Foreign % CHG	Foreign \$
COZAAR / HYZAAR	6%	3,558	1%	1,247	9%	2,311
FOSAMAX	-49%	1,553	-75%	498	-1%	1,054
SINGULAIR	2%	4,337	-6%	2,825	19%	1,511
Vaccines:						
GARDASIL	-5%	1,403	-13%	1,041	26%	362
ROTATEQ	27%	665	24%	618	83%	46
ZOSTAVAX	32%	312	32%	312	N/A	-
OTHER VIRAL VACCINES ⁽¹⁾	-6%	1,268	-8%	1,175	38%	94
HEPATITIS VACCINES ⁽²⁾	-47%	148	-52%	112	-21%	36
OTHER VACCINES ⁽³⁾	-13%	355	-32%	206	38%	149
Other Reported Products:						
ARCOXIA	15%	377	N/A	-	15%	377
CANCIDAS	11%	596	-21%	100	21%	496
COSOPT / TRUSOPT	-1%	781	-17%	291	12%	491
CRIVAN / STOCRIN	-11%	275	-36%	13	-10%	262
EMEND	29%	264	24%	172	41%	92
INVANZ	39%	265	32%	138	48%	127
ISENTRESS	*	361	*	202	*	159
JANUVIA	*	1,397	79%	1,110	*	287
JANUMET	*	351	*	308	*	43
MAXALT	13%	529	13%	354	14%	175
PRIMAXIN	-	760	-22%	163	8%	598
PROPECIA	6%	429	-1%	151	10%	278
PROSCAR	-21%	324	-79%	12	-12%	311
TIMOPTIC / TIMOPTIC XE	2%	122	-10%	7	2%	115
VASOTEC / VASERETIC	-28%	357	N/A	-	-28%	357
ZOCOR	-25%	660	-59%	75	-16%	585
ZOLINZA	40%	15	34%	14	*	1

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	FY '08	% CHG	VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	\$ 23,850	-1%	-4	=	3
U.S. (\$ MM)	13,370	-9%	-11	2	N/A
Foreign (\$ MM)	10,480	10%	7	-4	7